Division of Medical Pharmacology, Leiden/Amsterdam Center for Drug Research, Medical Faculty, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands.
Stress. 1997 Oct;2(1):13-20. doi: 10.3109/10253899709014734.
Dexamethasone poorly penetrates in brain. A tracer amount of [3H]-dexamethasone administered to adrenalectomized rats or mice is poorly retained by glucocorticoid receptors in brain, while pituitary corticotrophs containing equivalent amounts of these receptors accumulate and retain large amounts of this synthetic steroid. However, adrenalectomized mice with a genetic disruption of the multiple drug resistance (mrd1a) gene have a tenfold increase of [3H]-dexamethasone uptake in brain glucocorticoid target sites reaching levels observed in the pituitary. These data demonstrate that dexamethasone is extruded from brain by the mrd1a-encoded P-glycoproteins. The data support the concept of a pituitary site of action of dexamethasone in blockade of stress-induced ACTH release, which implies that chronic dexamethasone treatment does not replace the endogenous corticosteroids depleted from brain mineralocorticoid (MRs) and glucocorticoid receptors (GRs). Dexamethasone, therefore, causes a profound disturbance in the balance of these two receptor types in hippocampus, which is an unfavourable condition threatening the neuronal integrity of this brain structure through the expression of noxious genes.
地塞米松难以穿透血脑屏障。给肾上腺切除的大鼠或小鼠注射微量的[3H] - 地塞米松后,脑内糖皮质激素受体对其摄取很少,而含有等量这些受体的垂体促肾上腺皮质激素细胞却能积累并保留大量这种合成类固醇。然而,具有多药耐药(mrd1a)基因遗传缺陷的肾上腺切除小鼠,其脑内糖皮质激素靶位点对[3H] - 地塞米松的摄取增加了10倍,达到垂体中观察到的水平。这些数据表明,地塞米松是由mrd1a编码的P - 糖蛋白从脑中排出的。这些数据支持了地塞米松在垂体部位发挥作用以阻断应激诱导的促肾上腺皮质激素释放的概念,这意味着长期地塞米松治疗并不能替代从脑盐皮质激素(MRs)和糖皮质激素受体(GRs)中耗尽的内源性皮质类固醇。因此,地塞米松会严重扰乱海马体中这两种受体类型的平衡,这种不利状况会通过有害基因的表达威胁到该脑结构的神经元完整性。